ChemAxon and Simmaren form strategic partnership to accelerate the development of new software for the prediction of human drug metabolism

Budapest, Hungary and Auckland, New Zealand, December 12, 2017   In recognition of the growing problem caused by the cost of drugs failing in the clinical phase – ChemAxon and Simmaren joined in a partnership to create new drug metabolite prediction technology. Simmaren will build new software for the prediction of xenobiotic metabolites based on…

Read More

Drug projects fail constantly

The estimated average pre-tax industry cost per new prescription drug approval (inclusive of failures and capital costs) is $2.6 billion.1 The processes of discovery and clinical trials amounts to approximately 12 years from research lab to the patient. For every 25,000 compounds that start in the laboratory, 25 are tested in humans, 5 make it…

Read More